Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Treasury Shares: 2019-2025

Historic Treasury Shares for Nurix Therapeutics (NRIX) over the last 5 years, with Aug 2025 value amounting to $2.7 million.

  • Nurix Therapeutics' Treasury Shares rose 28.99% to $2.7 million in Q3 2025 from the same period last year, while for Aug 2025 it was $2.7 million, marking a year-over-year increase of 28.99%. This contributed to the annual value of $2.0 million for FY2024, which is 56.98% up from last year.
  • Nurix Therapeutics' Treasury Shares amounted to $2.7 million in Q3 2025, which was down 9.79% from $3.0 million recorded in Q2 2025.
  • Over the past 5 years, Nurix Therapeutics' Treasury Shares peaked at $3.0 million during Q1 2025, and registered a low of $971 during Q1 2021.
  • For the 3-year period, Nurix Therapeutics' Treasury Shares averaged around $1.9 million, with its median value being $2.0 million (2024).
  • Per our database at Business Quant, Nurix Therapeutics' Treasury Shares slumped by 99.90% in 2024 and then spiked by 195,381.91% in 2025.
  • Quarterly analysis of 5 years shows Nurix Therapeutics' Treasury Shares stood at $20,000 in 2021, then spiked by 3,824.12% to $784,824 in 2022, then spiked by 58.77% to $1.2 million in 2023, then spiked by 56.98% to $2.0 million in 2024, then climbed by 28.99% to $2.7 million in 2025.
  • Its Treasury Shares stands at $2.7 million for Q3 2025, versus $3.0 million for Q2 2025 and $3.0 million for Q1 2025.